S-Petasin
S-Petasin is a phosphodiesterase (PDE) inhibitor with IC50 values of 25.5 μM and 17.5 μM for PDE3 and PDE4, respectively. S-Petasin inhibits cholesterol side-chain cleavage enzyme, 11β-hydroxylase, PPAR-γ, and iNOS induction at RNA and protein levels. S-Petasin induces apoptosis, activates caspases, cleaves PARP, modulates mitochondrial membrane permeability, and regulates BCL2/BAX, p53, Bcl-XL, MMP-2, MMP-9, p21, CDK4, and cyclin D1 expression. S-Petasin reduces inflammatory cell accumulation, cytokine and IgE levels, and enhances serum IgG2a levels. S-Petasin relaxes isolated sensitized guinea pig trachealis and exhibits gastrointestinal anti-spasmodic activity. S-Petasin reduces tonsillitis severity and asthmatic attack frequency. S-Petasin can be used for the research of prostate cancer, obesity, melanoma, allergic asthma, asthma, and peritonitis.
For research use only. We do not sell to patients.
- CAS No.: 70238-51-6
- Formula: C19H26O3S
- Molecular Weight:334.47
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
|
PDE3 25.5 μM (IC50) |
PDE4 17.5 μM (IC50) |
PDE3 25.3 μM (Ki) |
PDE4 18.1 μM (Ki) |
PPARγ |
iNOS |
In Vitro
S-Petasin (10 nM-10 μM; 3-4 days) dose-dependently inhibits proliferation of LNCaP, DU145, and PC3 human prostate cancer cells, but not PC3 cells[1].
S-Petasin (0.1-10 μM; 12-18 h) activates caspase cascades and induces PARP cleavage in LNCaP, DU145, and PC3 human prostate cancer cells, consistent with induction of apoptosis[1].
S-Petasin (0.1-10 μM; 8-12 h) induces mitochondrial membrane permeability disruption, cytochrome c release, and modulates expression of BCL2 family proteins and p53 in LNCaP, DU145, and PC3 human prostate cancer cells, triggering mitochondria-mediated apoptosis[1].
S-petasin (0.31-1.55 μM; 8 days) dose-dependently inhibits 3T3-L1 pre-adipocyte differentiation, reducing lipid accumulation to 30.18% at the highest tested concentration[2].
S-petasin (0.31-1.55 μM; 8 days) dose-dependently inhibits triglyceride accumulation in differentiated 3T3-L1 adipocytes, reducing TG content to 61.04% at the highest tested concentration[2].
S-petasin (0.31-1.55 μM) dose-dependently inhibits PPAR-γ expression in 3T3-L1 cells, with greater inhibition observed after 8 days of differentiation treatment than after 24 h[2].
S-petasin (0.31-1.55 μM; 8 days) dose-dependently inhibits the expression of PPAR-γ target genes (HMGCR, FAS, CD36, Glut4, A-FABP, LPL) in differentiated 3T3-L1 adipocytes[2].
S-Petasin (2-160 μM; 24 h) potently inhibits proliferation of B16F10 cells (IC50 = 42.16 μM) and A375 cells (IC50 = 36.90 μM) after 24 h of treatment, as measured by MTT assay[3].
S-Petasin (10-40 μM; 24 h) induces apoptosis of B16F10 cells and A375 cells in a concentration-dependent manner after 24 h of treatment, as measured by Annexin V/PI flow cytometry[3].
S-Petasin (10-40 μM; 24 h) induces apoptosis of B16F10 cells and A375 cells after 24 h of treatment by downregulating pro-apoptotic precursors and upregulating activated cleavage products of caspase 9, caspase 3, and PARP-1[3].
S-Petasin (10-40 μM; 24 h) regulates downstream p53 target genes in B16F10 cells and A375 cells after 24 h of treatment by decreasing nuclear NF-κB, MMP-2, MMP-9, Bcl-2, Bcl-xL, CDK4, and cyclin D1 expression, and increasing Bax and p21 expression, all in a concentration-dependent manner[3].
S-Petasin (4-40 μM; up to 24 h) inhibits migration of B16F10 cells and A375 cells in a concentration-dependent manner over 24 h, as measured by wound healing assay[3].
S-Petasin (4-40 μM; 24 h) inhibits invasion of B16F10 cells and A375 cells through Max Gel ECM in a concentration-dependent manner after 24 h of treatment[3].
S-Petasin (10-40 μM; 24 h) activates p53 expression at mRNA and protein levels in a concentration-dependent manner in B16F10 cells and A375 cells after 24 h of treatment[3].
S-Petasin (1-100 μM; 30 min) competitively inhibits PDE3 and PDE4 from guinea pig lungs and hearts with IC50 values of 25.5 μM and 17.5 μM, respectively, and does not inhibit PDE1, PDE2, or PDE5 at concentrations up to 100 μM[4].
S-Petasin potently inhibits antigen-induced degranulation in RBL-2H3 mast cells with an IC50 of ~1 nM[5].
S-Petasin (1-10 μM; 1 h preincubation, 24 h LPS stimulation) concentration-dependently inhibits LPS-induced iNOS protein and mRNA expression, NO and PGE2 production in mouse peritoneal macrophages, with significant effects at 1, 3, 5, and 10 μM[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LNCaP, DU145, PC3 (human prostate cancer cell lines)
-
Concentration:0.1 μM, 1 μM, 10 μM
-
Incubation Time:12, 18 h
-
Result:Reduced levels of procaspase 3, 7, 8, and 9 in LNCaP cells after 12 and 18 h.
Reduced levels of procaspase 3, 8, and 9 in DU145 cells after 12 and 18 h (procaspase 7 levels were unchanged).
Reduced levels of procaspase 3, 7, 8, and 9 in PC3 cells after 12 and 18 h.
Induced dose-dependent cleavage of PARP in all three cell lines after 12 and 18 h.
-
Cell Line:LNCaP, DU145, PC3 (human prostate cancer cell lines)
-
Concentration:0.1 μM, 1 μM, 10 μM
-
Incubation Time:8, 12 h
-
Result:Increased release of cytochrome c from mitochondria in LNCaP cells after 8 and 12 h.
Increased release of cytochrome c from mitochondria, downregulated BCL2, and downregulated p53 in PC3 cells after 8 and 12 h.
Increased release of cytochrome c from mitochondria, upregulated p53, upregulated BAX, downregulated BCL2, and induced BAX translocation in DU145 cells after 8 and 12 h.
-
Cell Line:B16F10 murine melanoma cells, A375 human melanoma cells
-
Concentration:10-40 μM
-
Incubation Time:24 h
-
Result:Increased the proportion of Annexin V and PI positive cells in a concentration-dependent manner in both B16F10 and A375 cells.
-
Cell Line:B16F10 murine melanoma cells, A375 human melanoma cells
-
Concentration:10 μM, 20 μM, 40 μM
-
Incubation Time:24 h
-
Result:Decreased expression of pro-caspase 9, pro-caspase 3, and pro-PARP-1, while upregulated expression of cleaved-caspase 9, cleaved-caspase 3, and cleaved-PARP-1 in both B16F10 and A375 cells.\nDecreased nuclear NF-κB expression and suppressed MMP-2 and MMP-9 expression in a dose-dependent manner in both B16F10 and A375 cells.
Downregulated Bcl-2 and Bcl-xL expression, while upregulating Bax expression in a dose-dependent manner in both B16F10 and A375 cells.
Upregulated p21 expression, while suppressing CDK4 and cyclin D1 expression in a dose-dependent manner in both B16F10 and A375 cells.
-
Cell Line:B16F10 murine melanoma cells, A375 human melanoma cells
-
Concentration:10 μM, 20 μM, 40 μM
-
Incubation Time:24 h
-
Result:Reduced the number of migrated B16F10 and A375 cells in a dose-dependent manner, with statistically significant inhibition at all tested concentrations.
-
Cell Line:B16F10 murine melanoma cells, A375 human melanoma cells
-
Concentration:4 μM, 10 μM, 20 μM, 40 μM
-
Incubation Time:24 h
-
Result:Reduced the number of invaded B16F10 and A375 cells in a dose-dependent manner, with statistically significant inhibition at all tested concentrations.
In Vivo
S-Petasin (1 mg/kg; i.p.; 1 h before each ovalbumin nebulization) inhibits ovalbumin-induced accumulation of eosinophils, macrophages, and lymphocytes in BALB/c mouse bronchoalveolar lavage fluid, reducing total cell counts by 80% relative to untreated asthmatic mice[5].
S-Petasin (1 mg/kg; i.p.; single dose 1 h prior to LPS injection) reduces LPS-induced accumulation of total peritoneal cells, polymorphonuclear leukocytes, and mononuclear leukocytes in C57BL/6 mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 8-12 weeks old, allergic asthma model via OVA sensitization and challenge)[4]
-
Dosage:10 μmol/kg; 30 μmol/kg
-
Administration:s.c.; 2 hours before, 6 and 24 hours after secondary OVA provocation
-
Result:Attenuated the enhanced pause (P_enh) value induced by 50 mg/mL methacholine in a dose-dependent and significant manner.
Suppressed increases in total inflammatory cells, neutrophils, and eosinophils in BALF in a significant manner.
Suppressed increases in lymphocytes in BALF at 30 μmol/kg dose, while 10 μmol/kg dose had no effect.
Left macrophage counts in BALF unchanged at both doses.
Suppressed increases in BALF levels of IL-2, IL-5, TNF-α, and IFN-γ in a significant manner at both doses.
Suppressed increases in BALF IL-4 levels at 30 μmol/kg dose, while 10 μmol/kg dose had no effect.
Reversed the reduction in serum total IgG2a levels in a significant manner at 30 μmol/kg dose.
Suppressed increases in serum total IgE, serum OVA-specific IgE, and BALF OVA-specific IgE in a dose-dependent and significant manner at both doses.
Suppressed increases in BALF total IgE levels at 30 μmol/kg dose, while 10 μmol/kg dose had no effect.
-
Animal Model:BALB/c (male, 6-week-old, adapted for 1 week prior to experimentation; asthma induced by intraperitoneal ovalbumin + alum on days 1 and 14, nebulized ovalbumin exposure on days 28-30)[5]
-
Dosage:1 mg/kg
-
Administration:i.p.; 1 h before each ovalbumin nebulization; 3 doses (days 28, 29, 30)
-
Result:Blunted ovalbumin-induced increase in total BALF cell number by approximately 80%.
Almost completely inhibited accumulation of macrophages and lymphocytes to PBS-treated basal levels.
Inhibited eosinophil accumulation by approximately 36%.
-
Animal Model:C57BL/6 (peritonitis induced by intraperitoneal 1 mg/kg LPS)[5]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose 1 h prior to LPS injection
-
Result:Reduced total peritoneal cell counts by 36% relative to LPS-induced controls.
Inhibited polymorphonuclear leukocyte accumulation by approximately 37%.
Inhibited mononuclear leukocyte accumulation by approximately 42%.
Did not significantly alter macrophage counts.
Chemical Information
-
CAS No. 70238-51-6
-
Molecular Weight 334.47
-
Formula C19H26O3S
-
SMILES
C[C@@H]([C@@H](CCC1=CC2=O)OC(/C=C\SC)=O)[C@@]1(C)C[C@H]2C(C)=C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Ovalbumin-Induced Allergic Airway Inflammation
Ovalbumin-induced allergic airway inflammation is a mouse model in which systemic sensitization to ovalbumin, usually with aluminum hydroxide adjuvant, is followed by airway ovalbumin challenge to induce allergic airway inflammation, eosinophil recruitment, mucus production, serum antigen-specific IgE, Th2 cytokine responses, and airway hyperresponsiveness to methacholine. The model is used to study allergen-driven airway inflammation and asthma-like immune responses, but it does not reproduce every feature of human asthma. The main readouts are bronchoalveolar lavage fluid cellularity, lung histopathology, airway hyperresponsiveness, serum OVA-specific IgE, and cytokines such as IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid or lung samples. Eosinophilia and Th2 cytokines reflect allergic type 2 inflammation, while methacholine responsiveness provides a functional airway-reactivity endpoint.
-
Zymosan-Induced Peritonitis
Zymosan-induced peritonitis is a sterile acute-inflammation model produced by intraperitoneal injection of zymosan, a yeast cell-wall particle preparation, followed by quantification of leukocyte recruitment and soluble inflammatory mediators in peritoneal lavage fluid. Low-dose zymosan peritonitis is commonly used as a self-resolving acute inflammation model in which neutrophil recruitment occurs early and monocyte/macrophage accumulation follows later. The assay readouts include total peritoneal leukocyte number, differential neutrophil and monocyte/macrophage counts, peritoneal cytokines and chemokines, plasma or peritoneal exudation, and optional lipidomic or metabolomic changes during inflammation and resolution. Early neutrophil recruitment after zymosan depends strongly on complement and mast-cell C5a receptor signaling, whereas later monocyte recruitment is linked to MCP-1/CCL2 production.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Transepithelial/transendothelial electrical resistance assay
TEER measures electrical resistance across epithelial or endothelial monolayers cultured on permeable supports, and the readout reflects ionic conductance through the cell barrier, especially the paracellular pathway regulated by junctional integrity. TEER can be measured without destroying the monolayer and is commonly used before or during transport, permeability, barrier-disruption, and barrier-maturation experiments. TEER values are influenced by biological maturation and technical conditions; reported factors include temperature, medium formulation, passage number, electrode geometry, membrane properties, and junctional length during early monolayer maturation. Therefore, TEER should be interpreted with blank-insert subtraction, area normalization, repeated readings, and, when possible, orthogonal barrier readouts such as FITC-dextran flux or tight-junction staining.
Purity & Documentation
References
[1]. Wang ZH, et al. Cytotoxic effect of s-petasin and iso-s-petasin on the proliferation of human prostate cancer cells. Anticancer Res. 2015;35(1):191-199. [Content Brief]
[2]. Guo L, et al. S-Petasin isolated from Petasites japonicus exerts anti-adipogenic activity in the 3T3-L1 cell line by inhibiting PPAR-γ pathway signaling. Food Funct. 2019 Jul 17;10(7):4396-4406. [Content Brief]
[3]. Guo L, et al. S-petasin induces apoptosis and inhibits cell migration through activation of p53 pathway signaling in melanoma B16F10 cells and A375 cells. Arch Biochem Biophys. 2020;692:108519. [Content Brief]
[4]. Shih CH, et al. S-Petasin, the Main Sesquiterpene of Petasites formosanus, Inhibits Phosphodiesterase Activity and Suppresses Ovalbumin-Induced Airway Hyperresponsiveness. Evid Based Complement Alternat Med. 2011;2011:132374. [Content Brief]
[5]. Lee KP, et al. Therapeutic effects of s-petasin on disease models of asthma and peritonitis. Biomol Ther (Seoul). 2015;23(1):45-52. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)